106 related articles for article (PubMed ID: 1283793)
1. Vitronectin modulates glycosaminoglycan dependent reactions of protein C inhibitor.
Seiffert D; Geiger M; Ecke S; Binder BR
Thromb Haemost; 1992 Dec; 68(6):657-61. PubMed ID: 1283793
[TBL] [Abstract][Full Text] [Related]
2. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
España F; Estellés A; Fernández PJ; Gilabert J; Sánchez-Cuenca J; Griffin JH
Thromb Haemost; 1993 Dec; 70(6):989-94. PubMed ID: 8165623
[TBL] [Abstract][Full Text] [Related]
3. Limited proteolysis of vitronectin by plasmin destroys heparin binding activity.
Sane DC; Moser TL; Greenberg CS
Thromb Haemost; 1991 Sep; 66(3):310-4. PubMed ID: 1720904
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion.
Elia C; Cassol E; Sidenius N; Blasi F; Castagna A; Poli G; Alfano M
J Leukoc Biol; 2007 Nov; 82(5):1212-20. PubMed ID: 17704294
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tissue kallikrein by protein C inhibitor. Evidence for identity of protein C inhibitor with the kallikrein binding protein.
Ecke S; Geiger M; Resch I; Jerabek I; Sting L; Maier M; Binder BR
J Biol Chem; 1992 Apr; 267(10):7048-52. PubMed ID: 1313031
[TBL] [Abstract][Full Text] [Related]
6. Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma.
España F; Estelles A; Griffin JH; Aznar J
Thromb Haemost; 1991 Jan; 65(1):46-51. PubMed ID: 1850876
[TBL] [Abstract][Full Text] [Related]
7. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
8. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
9. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.
Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN
Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984
[TBL] [Abstract][Full Text] [Related]
10. Heparin stimulation of the inhibition of activated protein C and other enzymes by human protein C inhibitor--influence of the molecular weightof heparin and ionic strength.
Aznar J; España F; Estellés A; Royo M
Thromb Haemost; 1996 Dec; 76(6):983-8. PubMed ID: 8972021
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1.
Kanse SM; Chavakis T; Al-Fakhri N; Hersemeyer K; Monard D; Preissner KT
J Cell Sci; 2004 Jan; 117(Pt 3):477-85. PubMed ID: 14679304
[TBL] [Abstract][Full Text] [Related]
12. Heparin binding of protein-C inhibitor--analysis of the effect of heparin on the interaction of protein-C inhibitor with tissue kallikrein.
Ecke S; Geiger M; Binder BR
Eur J Biochem; 1997 Sep; 248(2):475-80. PubMed ID: 9346305
[TBL] [Abstract][Full Text] [Related]
13. Protein C and its inhibitor in malignancy.
Suzuki K; Hayashi T
Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
[TBL] [Abstract][Full Text] [Related]
14. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
15. A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard.
España F; Sanchez-Cuenca J; Vera CD; Estelles A; Gilabert J
J Lab Clin Med; 1993 Dec; 122(6):711-9. PubMed ID: 7504042
[TBL] [Abstract][Full Text] [Related]
16. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
17. Protein C inhibitor from human plasma: characterization of native and cleaved inhibitor and demonstration of inhibitor complexes with plasma kallikrein.
Laurell M; Stenflo J
Thromb Haemost; 1989 Nov; 62(3):885-91. PubMed ID: 2556811
[TBL] [Abstract][Full Text] [Related]
18. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
[TBL] [Abstract][Full Text] [Related]
19. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
[TBL] [Abstract][Full Text] [Related]
20. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
